Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1148
Peer-review started: July 20, 2020
First decision: September 24, 2020
Revised: October 1, 2020
Accepted: October 26, 2020
Article in press: October 26, 2020
Published online: December 27, 2020
Processing time: 150 Days and 14.4 Hours
Core Tip: Intrahepatic cholangiocarcinoma (iCCA) is a histopathologically and molecularly heterogeneous tumor. Recent developments in genomic profiling have revealed several molecular markers for poor prognosis and activation of oncogenic pathways. Exploration of molecular characteristics of iCCA in each patient is a major challenge in a clinical setting, and there exists no effective molecular-based targeted therapy. Therefore, the analysis of relevance between molecular and clin-icopathological features is very important. The present analysis showed that the molecular subtypes of iCCA have distinct clinicopathologic features and prognostic differences. For developing effective targeted and personalized therapies based on clinical and molecular understanding, future additional large scale studies are needed.
